OneDigital Investment Advisors LLC Takes Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

OneDigital Investment Advisors LLC acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 657 shares of the medical research company’s stock, valued at approximately $220,000.

A number of other institutional investors also recently added to or reduced their stakes in BIO. Capital Advisors Ltd. LLC boosted its stake in Bio-Rad Laboratories by 193.8% in the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 62 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after buying an additional 45 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth $51,000. Headlands Technologies LLC purchased a new stake in shares of Bio-Rad Laboratories during the second quarter valued at $51,000. Finally, Quarry LP acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $59,000. Institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target for the company. Royal Bank of Canada increased their price target on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Citigroup lifted their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Bio-Rad Laboratories has an average rating of “Moderate Buy” and an average target price of $391.80.

Insider Buying and Selling

In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This represents a 28.41 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James Barry sold 623 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. This trade represents a 80.91 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by insiders.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO opened at $332.91 on Friday. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The firm’s 50 day simple moving average is $340.52 and its 200-day simple moving average is $315.68. The stock has a market capitalization of $9.32 billion, a price-to-earnings ratio of -12.18 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. The business had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The business’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.33 EPS. Analysts expect that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.